Sorafenib, a potent inhibitor of the V600E B-RAF protein, which is also a well-known multi-targeted kinase inhibitor, has shown pronounced activity in combination with cetuximab in V600E BRAF-mutant CRC cells [118]. Here, BRAF is linked to colorectal carcinoma.